“Global Embolization Particle Market by Manufacturers, Countries, Type and Application, Forecast to 2023 Report “Provides In-Depth Analysis of Parent Market Trends, Macro-Economic Indicators and Governing Factors Along With Market Attractiveness as Per Segments. The global embolization particle market is expected to grow at a CAGR of 9.64% during the forecast period 2017-2023.
MarketResearchFuture.com adds “Embolization Particle Market – 2018 Global Analysis, Growth, Trends and Opportunities Research Report forecasting to 2023” reports to its database.
Embolization Particle Market – Overview:
Embolization is a minimally invasive therapy to stop bleeding and blood flow to a tumour in order to shrink it or for removal. In this procedure some embolized particles or substances are injected into the vein of the patient to block or reduce the blood flow to cancer cells. Embolization is one of the best options for patients with tumours that cannot be removed by surgery. Embolization does reduce some of the blood supply to the normal liver tissue, so it may not be a good option for some patients whose liver has been damaged by diseases such as hepatitis or cirrhosis.
Technological advancement and rising demand for diagnostics and treatment options for cancer are key players in the market. Moreover, increasing number of patients with various oncological conditions have increased the demand for different embolization particles in the market. Furthermore, in the treatment of various types of cancer such as liver cancer, brain cancer, lung cancer embolization particle are used. Developing regions provide ample opportunities for the growth of the embolization particle market.
Key Players in the Embolization Particle Market:
Boston Scientific Corporation, Guerbet, BTG International Ltd, Medtronics, Sirtex, Terumo, and Merit Medical are the key players in the global embolization particle market.
Strategic approaches adopted help the major players to sustain their growth in the market and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.
You can get easy access to sample report here, please click: https://www.marketresearchfuture.com/sample_request/4815 .
Integrate Embolization Particle:
July, 2016: Integrated Embolization Particle received clearance from the FDA for its nuvis Single-Use Arthroscope. It is the first FDA-approved disposable rigid endoscope.
In February, 2016: Integrated Embolization Particle demonstrated its nuvis Single-Use Arthroscope at the 2016 American Academy of Orthopaedic Surgeons (AAOS) Meeting in Orlando, USA.
September, 2016: Sirtex expanded in Europe and included health professionals from United Kingdom, Belgium, Spain and Italy
September, 2014: Sirtex Medical Inc. expanded business into Brazil, and experienced record growth
March, 2014: Sirtex and Guerbet collaborated on clinical studies in primary and secondary liver cancer
Boston Scientific Corporation:
March, 2017: Boston Scientific Corporation Announced Agreement to Acquire Symetisenergy to reduce the amount of excess smooth muscle tissue in the airways.
November, 2015: Boston Scientific Corporation acquired interventional radiology business of CeloNova Biosciences
November, 2015: Guerbet completed the acquisition of Mallinckrodt’s Contrast Media and Delivery Systems
September, 2014: Guerbet received the approval from French regulatory authorities for the use of its Lipiodol Ultra-Fluid product for chemoembolization of hepatocellular carcinoma
BTG International Ltd:
February, 2017 BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology
October, 2017: First patient treated with microscopic beads pre-loaded with a targeted cancer drug and visible on CT scans
April, 2016: BTG announced the United States launch of LC Bead LUMI, ground-breaking radiopaque embolic bead
October, 2015: BTG and MIRADA Collaborated to develop Dosimetry Software Solutions to Optimise Radioembolisation Therapy in Interventional Oncology
June, 2017: Merit Medical’s Embosphere Microspheres received FDA 513(f)(2) (de novo) classification for prostatic artery embolization indication
February, 2017: Merit Medical acquired products from Argon Medical Devices and Catheter Connections, Inc.
Any query or specific requirement? Ask to our industry expert, please click: https://www.marketresearchfuture.com/enquiry/4815 .
Global Embolization Particle Market:
North America dominates the Americas embolization particle market. North America is further segmented into the U.S. and Canada. The U.S. holds the major share of the market owing to a well-developed economy, rising prevalence of cancer, and increasing government support for research & development. South America is still a developing region in terms of the infrastructure and technology.
According to American Cancer Society, (2017) About 222,500 new cases of lung cancer (116,990 in men and 105,510 in women) and about 155,870 deaths from lung cancer (84,590 in men and 71,280 in women) in U.S. As per American Cancer Society’s (2017) estimated About 63,990 new cases of kidney cancer (40,610 in men and 23,380 in women) will occur and about 14,400 people (9,470 men and 4,930 women) will die from this disease. According to the WHO estimates, brain associated disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
- The market for embolization particle is expected to reach around USD 1,909.76 million by 2023.
- Radioembolization accounts the largest market share in 2016 and which is projected grow at a CAGR of 10.01% during the forecast period from 2017-2023.
- Americas hold the largest share of the embolization particle market and is expected to reach USD 703.13 million by 2023.
- Asia Pacific is the fastest growing region across the globe and expected to grow at a rate of CAGR 10.11% during the forecast period.
The global embolization particle market is segmented on the basis of product type, application, level of occlusion and end user.
On the basis of the product type the embolization particle market is further segmented into radioembolization and drug eluting beads.
On the basis of applications, the market is segmented into oncology, urology, peripheral vascular disease, neurology, and others.
On the basis of level of occlusion the market is segmented into proximal and distal.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory services and others.
What makes our report unique?
1) An extensive research study on the Global Embolization Particle market, and its entire ecosystem, describes the market trends, drivers, restraints and opportunities of the Embolization Particle market.
2) We provide you the longest possible market segmentation based on type of products, procedures and geography and describe the market share region wise.
3) The report gives a bird eyes view on the competitive landscape which includes mergers and acquisitions, collaborations, market strategies, and new product launches.
…CONTINUED FOR TOC
Feel free to get in touch for discounts and customized details, please click: https://www.marketresearchfuture.com/check-discount/4815 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312